Medical Xpress

The role of fibronectin in BRAF-mutant thyroid cancer treatment

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF ...
Business Wire

JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor, in Combination With Dabrafenib for Advanced Solid Tumors With BRAF V600E/K mutations

CHICAGO & SHANGHAI--(BUSINESS WIRE)--JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic ...
Medical Xpress

Small molecule inhibitors restore normal BRAF structure, offering insight into cancer-causing mutations

Frequently affected by so-called oncogenic mutations, BRAF is implicated in several human cancers. In its normal state, the BRAF protein remains confined to an inactive form, through a mechanism of ...
Agence France-Presse

European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation

Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now ...
ascopubs.org

The role of activating mutations of KRAS, BRAF, and PIK3CA pathway convergence at the transcriptional level and prediction of treatment response to cetuximab in colorectal cancer.

The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does ...